Sign In
Buy CRSP
$46.99
-0.790 (-1.65%)
At Close: Jul 20, 2026
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
10:37am, Thursday, 08'th May 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
08:36am, Thursday, 08'th May 2025
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
02:17pm, Wednesday, 07'th May 2025
CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
08:40am, Wednesday, 07'th May 2025
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates.
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
08:39am, Wednesday, 07'th May 2025
CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
06:25pm, Tuesday, 06'th May 2025
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, wit
CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings
07:18am, Monday, 05'th May 2025
Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs.
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
04:44am, Monday, 05'th May 2025
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better position
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
06:50pm, Friday, 02'nd May 2025
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:00am, Friday, 02'nd May 2025
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
2 Beaten-Down Stocks With Incredible Upside Potential
05:14am, Wednesday, 30'th Apr 2025
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have signi
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
06:55pm, Thursday, 24'th Apr 2025
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
01:14pm, Thursday, 24'th Apr 2025
Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more.
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
07:05pm, Wednesday, 23'rd Apr 2025
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day.
